Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Journal of Controlled Release

Volumn 57, Issue 3, 1999, Pages 281-290

  Julyan, Peter J ^a   Seymour, Leonard W ^b   Ferry, David R ^b   Daryani, Sunil ^b   Boivin, Christopher M ^a   Doran, Jayne ^b   David, Marilyn ^b   Anderson, David ^b   Christodoulou, Christos ^b   Young, Annie M ^b   Hesslewood, Stuart ^c   Kerr, David J ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Asialoglycoprotein receptor; Doxorubicin; Galactose; HPMA copolymers; Imaging

Indexed keywords

ANTINEOPLASTIC AGENT; ASIALOGLYCOPROTEIN RECEPTOR; COPOLYMER; DOXORUBICIN; GALACTOSE; IODINE 123; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE];

ARTICLE; CASE REPORT; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER CELL CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; CARCINOMA, HEPATOCELLULAR; DAUNORUBICIN; DRUG CARRIERS; GALACTOSAMINE; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; POLYMETHACRYLIC ACIDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 0033013012     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00124-2     Document Type: Article

References (27)

1. Duncan R., Seymour L.W., O'Hare et al K.B. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release. 19:1992;331-346.
2. Seymour L.W., Ulbrich K., Steyger et al P.S. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F19 melanoma. Br. J. Cancer. 70:1994;636-641.
3. Duncan R. Polymer-drug conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
4. Duncan R., Cable H.C., Lloyd J.B., Rejmanova P., Kopecek J. Degradation of side-chains of N-(2-hydroxyproply)methacryamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 2:1983;1041-1046.
5. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumouritropic accumulation or proteins and the antitumour agent SMANCS. Cancer Res. 46:1986;6387-6392.
6. Seymour L.W. Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carr. Syst. 9:1992;135-187.
7. Cassidy J., Duncan R., Morrison et al G.J. Activity of N-(2-hydroxyproply)methacryamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 38:1989;875-879.
8. R. Duncan, P.A. Vasey, S.B. Kaye, J. Cassidy, Development of PK1 an HPMA copolymer doxorubicin conjugate, the CRC experience, Proc. of the EORTC Early Drug Development Meeting, Corfu, June 22-24, 1995, pp. 60-61.
9. Duncan R., Seymour L.W., Scarlett L., Lloyd J.B., Rejmanova P., Kopecek J. Fate of with pendent galactosamine residues after intravenous administration in rats. Biochim. Biophys. Acta. 880:1986;62-71.
10. 2 mice. Br. J. Cancer. 63:1991;859-866.
11. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
12. Fallon R.J., Schwartz A.L. Receptor-mediated delivery of drugs to hepatocytes. Adv. Drug Deliv. Rev. 4:1989;49-63.
13. Underhill D.M., Oensby D.A., Morton P.A., Schwartz A.L. Endocytosis and Iysosomal delivery of tissue plasminogen activating factor-inhibitor complexes in HEPG2 cells. Blood. 80:1992;2746-2754.
14. Lodish H.F. Recognition of complex oligosaccharides by the multi-subunit asialoglycoprotein receptor. Trends Biochem. Sci. 16:1991;374-377.
15. Pardridge W.M., Van Herle A.J., Naruse R.T., Fierer G., Costin A. In vivo quantification of receptor-mediated uptake of asialoglycoproteins by rat liver. J. Biol. Chem. 258:1983;990-994.
16. Clarke B.J., Oka J.A., Weigel P.H. Degradation of asialoglycoproteins mediated by the galactose receptor in isolated hepatocytes. J. Biol. Chem. 262:1987;17384-17392.
17. Trouet A., Jolles G. Targeting of daunorubicin by association with DNA or proteins:areview. Semin. Oncol. 11(4, Supplement 3):1984;64-72.
18. Virgolini I., Muller C., Klepetko W.et al. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br. J. Cancer. 61:1990;937-941.
19. Ceulemans F., Baurain R., Geubel A., Lesur B., Rolin-Van Swieten D., Trouet A. Pilotage des anthracyclines et hépatomes. Pathologie Biologie. 35:1983;61-68.
20. H.D. Burns, R.E. Gibson, R.F. Dannals, P.K.S. Siegl (Eds.), Nuclear Imaging in Drug Discovery, Development, and Approval, Birkhäuser, Boston, 1993.
21. Pimm M.V., Perkins A.C., Duncan R., Ulbrich K. Targeting of N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Targ. 1:1993;125-131.
22. Pimm M.V., Perkins A.C., Strohalm J., Ulbrich K., Duncan R. Gamma scintigraphy of the biodistribution of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Targ. 3:1996;375-383.
23. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J. Drug Targ. 3:1996;385-390.
24. Fraier D., Frigerio E., Pianezzola E., Benedetti M.S., Cassidy J., Vasey P. A sensitive procedure for the quantitation of free and n-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (pk1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase hplc with fluorometric detection. J. Pharm. Biomed. Anal. 13:1995;625-633.
25. Attali P., Prodhomme S., Pelletier G.et al. Prognostic factors in patients with hepatocellular carcinoma - attempts for the selection of patients with prolonged survival. Cancer. 59:1987;2108-2111.
26. Falkson G., Cnaan A., Simson I.W.et al. A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an eastern cooperative oncology group. Am. J. Clin. Oncol. Cancer Clin. Trial. 13:1990;510-515.
27. Mughal T.I. The role of interferon alpha in the management of cancers - current scenario. Saudi Med. J. 12:1991;454-460.